Find the newest developments in CAR-T cell therapy for lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and other subtypes. We report on clinical trials, product approvals, long-term efficacy data, and safety updates. Coverage includes both global progress and China’s expanding role in CAR-T treatment for lymphoma.
Five-year follow-up data from Yescarta (axi-cel) continues to demonstrate durable survival and long-term remission in patients with relapsed or refractory large B-cell lymphoma, supporting its role as a potential curative treatment and establishing a new standard of care in China.
A new real-world multicenter study in patients with relapsed or refractory large B-cell lymphoma shows that second-line CAR-T cell therapy is associated with a lower hematologic toxicity burden, improved safety profile, and favorable survival outcomes compared with later-line treatment settings.
A new modeling study reveals that lowering tumor burden before CAR-T infusion could significantly improve outcomes in lymphoma, offering a new strategy to enhance long-term remission.
New Phase II data from China demonstrate that relma-cel CAR-T therapy delivers high response rates and durable survival in heavily pretreated relapsed/refractory mantle cell lymphoma patients.
A Phase I study from Beijing reports highly promising results for CD7 CAR-T therapy in relapsed or refractory T-cell lymphoma, achieving a 92.5% response rate and 77.5% complete remission. The treatment showed encouraging survival outcomes, especially in patients who proceeded to allo-HSCT consolidation.
China approves a second indication for the homegrown CD19 CAR-T therapy Yorwida, bringing new hope to patients with relapsed or refractory large B-cell lymphoma.
On November 3, new clinical data were reported for a universal CD19/CD20-targeted CAR-T cell therapy (CT1190B) in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL), demonstrating promising efficacy and manageable safety.
Get a concise overview of the 2025 Chinese expert consensus on T-cell immunotherapy for aggressive B-cell lymphoma, including key updates, treatment highlights, and clinical insights.
Discover how CARTEYVA, a CD19-directed CAR-T therapy is advancing treatment for follicular lymphoma with promising results and local availability in China.
NMPA granted Breakthrough Therapy Designation for Carteyva (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) .
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.